Adaptimmune Therapeutics plc
NASDAQ: ADAP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Adrian G. Rawcliffe
- Employees
- 506
- Headquarters
- Abingdon, United Kingdom
- IPO year
- 2015
- Market cap
- $75.2M
- Website
- https://www.adaptimmune.com
Loading ADAP…
Loading profile data…Frequently asked questions about ADAP
What does Adaptimmune Therapeutics plc (ADAP) do?
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed...
Where does ADAP trade?
Adaptimmune Therapeutics plc (ADAP) trades on the NASDAQ Global Select.
What sector is ADAP in?
Adaptimmune Therapeutics plc (ADAP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Adaptimmune Therapeutics plc?
Adrian G. Rawcliffe is the chief executive officer of Adaptimmune Therapeutics plc (ADAP).
Where is Adaptimmune Therapeutics plc headquartered?
Adaptimmune Therapeutics plc is headquartered in United Kingdom.
Does ADAP pay a dividend?
Adaptimmune Therapeutics plc (ADAP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ADAP go public?
Adaptimmune Therapeutics plc (ADAP) completed its initial public offering in 2015.
Is ADAP an ADR?
Yes — ADAP is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Adaptimmune Therapeutics plc reporting and dividends follow the underlying issuer.